학술논문

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Document Type
Article
Source
In The Lancet 21-27 November 2015 386(10008):2059-2068
Subject
Primary Research
Articles
Language
ISSN
0140-6736